UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-A
FOR REGISTRATION OF
CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): January 6, 2009
BIOSPECIFICS TECHNOLOGIES CORP. |
(Exact name of registrant as specified in its charter) |
Delaware | 11-3054851 |
(State or incorporation or organization) | (I.R.S. Employer Identification No.) |
35 Wilbur Street, Lynbrook, New York | 11563 |
(Address of principal executive offices) | (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class | Name of each exchange on which |
To be so registered: | each class is to be registered: |
Common Stock | The Nasdaq Stock Market LLC |
If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box.
QIf this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box.
¨Securities Act registration statement file number to which this form relates: ____________ (if applicable)
Securities to be registered pursuant to Section 12(g) of the Act: None
Introductory Comment
Throughout this Current Report on Form 8-K, the terms "we," "us," "our" and "Company" refer to BioSpecifics Technologies Corp.
ITEM 1. DESCRIPTION OF REGISTRANTS SECURITIES TO BE REGISTERED
The capital stock to be registered hereby consists of shares of the Companys common stock, par value $0.001 per share (the "Common Stock"). Each share of our Common Stock entitles the holder thereof to one vote on each matter submitted to a vote of the stockholders of the Company. Subject to dividend preferences that may apply to any outstanding shares of our preferred stock, holders of our Common Stock will receive ratably any dividends our board of directors declares out of funds legally available for that purpose. In the event that the Company liquidates, dissolves or winds up its affairs, the holders of our Common Stock are entitled to share ratably in all assets remaining after payment of debts and other liabilities and any preferential amounts to which the holders of any outstanding shares of preferred stock shall be entitled to receive upon dissolution, liquidation, or winding up. Our Common Stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.
ITEM 2. EXHIBITS
Pursuant to the instructions as to exhibits, no exhibits are required to be filed herewith.
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
Date: January 6, 2009 |
BIOSPECIFICS TECHNOLOGIES CORP. |
(Registrant) |
|
/s/ Thomas L. Wegman | |
Thomas L. Wegman |
|
President |
|